RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

Company Overview

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Key Stats

• Today's Range: $1.25 to $1.30
• 50-Day Range: $0.36 to $0.50
• 52-Week Range: $0.31 to $7.70
• Volume: 139,747 shs
• Average Volume: 1.73 million shs
• Market Capitalization: $5.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/14/2018
• Today: 10/15/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RXII
• CIK: 1533040
• Web: www.rxipharma.com
• Phone: (508) 767-3861
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.45 million
• Net Margins: -4,990.20%
• Pretax Margin: N/A
• Return on Equity: -412.15%
• Return on Assets: -179.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 569.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.77 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 4,380,000
• Free Float: N/A
• Market Cap: $5.69 million
• Optionable: Not Optionable
• Beta: 2.07